Amsterdam - 14 September 2015 - LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company, Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics, has signed a definitive agreement under which it will be acquired by Agilent Technologies. Seahorse Bioscience, a privately held U.S. company which employs just under 200 people, was founded in 2001 and is headquartered in Billerica, Massachusetts. The company also has manufacturing operations in Chicopee, Massachusetts and regional offices in Copenhagen, Denmark, and Shanghai, China. Dr. Fouad Azzam, U.S. based Partner at LSP, served on the board of Directors of Seahorse. Seahorse Bioscience press release can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
Contact
Fouad Azzam, Partner LSP
Tel: +1 (781) 235 0321